Department of Internal Medicine, The Fourth People's Hospital of Nanning, Nanning, China.
Infectious Disease Laboratory, The Fourth People's Hospital of Nanning, Nanning, China.
CNS Neurosci Ther. 2024 Mar;30(3):e14437. doi: 10.1111/cns.14437. Epub 2023 Aug 31.
The use of two or more drugs carries the potential risk of drug-drug interactions (DDIs), which may result in adverse reactions. Some human immunodeficiency virus (HIV)-infected patients who receive antiretroviral therapy (ART) may require general anesthesia with propofol (PRL) before undergoing surgical treatment. Both PRL and ART drugs may lead to neuronal dysfunction, which can be accompanied by energy metabolism disorders. Neurons take in glucose mainly through glucose transporter 3 (Glut3) which is specifically expressed on the cell membranes of neurons. However, to date, no study has examined whether the DDIs of PRL and ART drugs interfere with glucose metabolism and Glut3 expression in neurons.
An in vitro model was constructed using the primary cultures of neurons. PRL and ART drugs (EFV, AZT, and 3TC), were added at different concentrations (low, medium, and high). The neurons were exposed to the drugs for 1, 4, 8, and 12 h. The optimal drug concentration and exposure time were selected. The cellular survival rate, glucose concentration, electrophysiology, and the expression of Glut3 were detected.
There were no significant changes in the cellular survival rates of the neurons that were exposed to both PRL and ART drugs at low concentrations for 1 h. However, the survival rates of the neurons decreased significantly as the drug concentrations and durations increased. The glucose concentration of the neurons that were exposed to both PRL and the ART drugs was significantly decreased. The glucose concentration of the neurons was not affected by any individual drug. The amplitude of the action potential and the expression of Glut3 were decreased in the neurons that were exposed to both PRL and ART drugs.
The main adverse reactions induced by the DDIs between PRL and the ART drugs were decreased glucose metabolism and neuronal damage, which were caused by inhibiting the expression of Glut3. More importantly, we found that decreases in glucose metabolism predated neuronal damage.
使用两种或更多种药物会带来药物-药物相互作用(DDI)的潜在风险,这可能导致不良反应。一些接受抗逆转录病毒治疗(ART)的人类免疫缺陷病毒(HIV)感染患者在接受手术治疗前可能需要使用异丙酚(PRL)进行全身麻醉。PRL 和 ART 药物都可能导致神经元功能障碍,伴有能量代谢紊乱。神经元主要通过葡萄糖转运蛋白 3(Glut3)摄取葡萄糖,Glut3 特异性表达于神经元的细胞膜上。然而,迄今为止,尚无研究探讨 PRL 和 ART 药物的 DDI 是否会干扰神经元中的葡萄糖代谢和 Glut3 表达。
构建神经元原代培养的体外模型。以不同浓度(低、中、高)加入 PRL 和 ART 药物(EFV、AZT 和 3TC)。将神经元暴露于药物 1、4、8 和 12 小时。选择最佳药物浓度和暴露时间。检测细胞存活率、葡萄糖浓度、电生理学和 Glut3 表达。
PRL 和 ART 药物低浓度暴露 1 小时,神经元细胞存活率无明显变化,但随着药物浓度和时间的增加,神经元存活率显著下降。暴露于 PRL 和 ART 药物的神经元葡萄糖浓度明显降低。单个药物对神经元葡萄糖浓度无影响。暴露于 PRL 和 ART 药物的神经元动作电位幅度和 Glut3 表达降低。
PRL 和 ART 药物相互作用引起的主要不良反应是葡萄糖代谢降低和神经元损伤,这是通过抑制 Glut3 表达引起的。更重要的是,我们发现葡萄糖代谢的降低先于神经元损伤。